QualityStocks News - TNI BioTech Appoints Quality Control Officers to Meet cGMP Standards and Lead Global Manufacturing Development

Share Article

Appointments to head the QC and QA operations for new pharmaceutical plant in Nicaragua.

It is important that IRT-103 (LDN), a treatment that has done so much good for some any people, be available at a quality and a price that benefits everyone.

QualityStocks would like to highlight TNI BioTech Inc., a publicly traded biotech company combating fatal diseases through the activation and mobilization of the body’s immune system using patented immunotherapy. The company's products and technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, and autoimmune diseases. They have been developing both active and adaptive forms of immunotherapies.

In the company’s news yesterday, TNI BioTech announced that it has entered an agreement with Pharmaceutical Care Consultants of South Florida, d/b/a Skip’s Pharmacy. As a result of this agreement, Dr. Henry “Skip” Lenz and Phil Giordano will join the company as heads of Quality Control and Quality Assurance for its pharmaceutical plant in Managua, Nicaragua. Dr. Lenz will be responsible for spearheading the company’s global manufacturing development.

Joining TNI BioTech’s executive leadership team, Dr. Lenz will be responsible for making sure all manufacturing meets cGMP standards. Dr. Lenz has held senior management positions in quality control, quality assurance, and production for multiple international manufacturers. Furthermore, Dr. Lenz held senior clinical research pharmacist positions with both domestic and international clinical research groups, including Senior Researcher at Key Pharmaceuticals in charge of the Research Division. Dr. Lenz founded and ran a contract research company that secured over 10 patents before being acquired by a mid-sized manufacturing company. Over the last fifteen years, Dr. Lenz has concentrated his efforts on relieving HIV/AIDS by participating in clinical applications of several novel therapies.

Dr. Lenz is a graduate of The Massachusetts College of Pharmacy and the University of Florida. Currently, he owns Pharmaceutical Care Consultants of South Florida d/b/a Skip’s Pharmacy in Boca Raton, Florida with his partner Phil Giordano. Skip’s Pharmacy is dedicated to providing the highest quality and optimum pharmaceutical care through its unique ability to formulate and compound drugs specifically to meet patient’s needs. Skip’s Pharmacy has been the leading outlet for the supply of LDN for over ten years.

Noreen Griffin, TNI BioTech’s CEO, underscored the company’s unwavering dedication to delivering a quality product and becoming a world-class leader in innovative therapeutics for patients afflicted with autoimmune and infectious diseases such as cancer and HIV/AIDS.

Dr. Lenz stated, “I was pleased to see that TNI was taking the manufacturing and distribution of IRT-103 (LDN) seriously. It is important that IRT-103 (LDN), a treatment that has done so much good for some any people, be available at a quality and a price that benefits everyone.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website